Did Keryx Biopharmaceuticals Inc Finally Turn The Corner?

Keryx Biopharmaceuticals  has been an awful stock to hold this year. Coming into this morning's earnings release, shares of the renal disease focused drug maker were down a gut wrenching 68% year to date. Understandably,